Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1

Leukemia. 2022 Nov;36(11):2729-2733. doi: 10.1038/s41375-022-01707-w. Epub 2022 Sep 23.

Authors

Warren Fiskus¹, Naval Daver¹, Steffen Boettcher², Christopher P Mill¹, Koji Sasaki¹, Christine E Birdwell¹, John A Davis¹, Kaberi Das¹, Koichi Takahashi¹, Tapan M Kadia¹, Courtney D DiNardo¹, Francis Burrows³, Sanam Loghavi¹, Joseph D Khoury¹, Benjamin L Ebert⁴, Kapil N Bhalla⁵

Affiliations

¹ The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
² University of Zurich and University Hospital Zurich, CH-8091, Zurich, Switzerland.
³ Kura Oncology, Inc., San Diego, CA, 92130, USA.
⁴ Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.
⁵ The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA. kbhalla@mdanderson.org.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Mutation
Myeloid-Lymphoid Leukemia Protein* / genetics
Nuclear Proteins / genetics

Substances

Myeloid-Lymphoid Leukemia Protein
Nuclear Proteins

Grants and funding